Pharmacology of Triamcinolone

Introduction/Overview

Triamcinolone is a synthetic glucocorticoid of intermediate potency that occupies a significant position in the therapeutic armamentarium for managing inflammatory, allergic, and autoimmune conditions. As a derivative of prednisolone, it exhibits potent anti-inflammatory and immunosuppressive properties while possessing a distinct pharmacokinetic and pharmacodynamic profile that informs its specific clinical applications. The drug is available in multiple salt forms, including acetonide, hexacetonide, and diacetate, each tailored for different routes of administration and durations of action. Its versatility is demonstrated by formulations designed for topical, oral, inhaled, intranasal, intra-articular, intralesional, and ophthalmic use.

The clinical relevance of triamcinolone stems from its ability to provide localized therapeutic effects with potentially reduced systemic exposure compared to oral corticosteroids, particularly when administered via targeted routes such as intra-articular or intralesional injection. It is a cornerstone in the management of conditions like rheumatoid arthritis, dermatological disorders, allergic rhinitis, asthma, and various ocular inflammations. Understanding its pharmacology is essential for optimizing therapeutic outcomes while minimizing the risk of adverse effects, which can range from local tissue atrophy to systemic hypercortisolism.

Learning Objectives

• Classify triamcinolone within the corticosteroid family and describe its chemical modifications that confer specific properties.
• Explain the molecular mechanism of action of triamcinolone, detailing its genomic and non-genomic effects on inflammatory pathways.
• Analyze the pharmacokinetic profile of triamcinolone, including how different salt forms and routes of administration influence absorption, distribution, metabolism, and excretion.
• Evaluate the approved therapeutic indications and common off-label uses of triamcinolone across various medical specialties.
• Identify major adverse effects, drug interactions, and special population considerations to ensure safe and effective clinical use.

Classification

Triamcinolone is classified within the broad therapeutic category of corticosteroids. A more precise classification delineates its position based on chemical structure, pharmacological potency, and clinical use.

Therapeutic and Chemical Classification

Therapeutically, triamcinolone is a glucocorticoid. It is not a mineralocorticoid, as it possesses negligible salt-retaining activity. Chemically, it is a fluorinated synthetic corticosteroid, specifically a 9α-fluoro-16α-hydroxyprednisolone derivative. The introduction of the fluorine atom at the 9α position significantly enhances glucocorticoid receptor binding affinity and anti-inflammatory potency compared to non-halogenated corticosteroids. The 16α-hydroxyl group is a critical structural feature that virtually abolishes mineralocorticoid activity, distinguishing it from other fluorinated steroids like dexamethasone and betamethasone.

Salt Forms and Potency

Triamcinolone is administered as various esterified salt forms, which profoundly affect its solubility and duration of action. These are not different drugs but prodrugs of the active triamcinolone base.

• Triamcinolone acetonide: This is the most commonly used ester. It is relatively insoluble, leading to a prolonged local depot effect when injected. It is the form found in many topical creams, intra-articular injections, and nasal sprays.
• Triamcinolone hexacetonide: This ester is even less soluble than the acetonide. It is used almost exclusively for intra-articular injections, where it provides the most prolonged anti-inflammatory effect among the triamcinolone esters, with a duration that may extend for several weeks to months.
• Triamcinolone diacetate: This form is more soluble than the acetonide or hexacetonide. It is used for both intra-articular injection and oral suspension, offering an intermediate duration of action.
• Triamcinolone base: Used in some oral formulations.

In comparative potency tables, triamcinolone is generally considered to have intermediate glucocorticoid potency. Its anti-inflammatory potency is approximately 5 times that of hydrocortisone. In contrast, its mineralocorticoid potency is essentially zero, which is a defining characteristic.

Mechanism of Action

The therapeutic and adverse effects of triamcinolone are mediated primarily through its action as an agonist at the intracellular glucocorticoid receptor (GR). The mechanism involves a complex interplay of genomic and non-genomic pathways that ultimately suppress the inflammatory and immune responses.

Genomic Mechanisms

This is the classical and primary mechanism, responsible for most effects that occur hours after administration. Being lipophilic, triamcinolone passively diffuses across the cell membrane into the cytoplasm. In the cytoplasm, it binds to the inactive glucocorticoid receptor, which is complexed with chaperone proteins including heat shock protein 90 (Hsp90). Receptor binding induces a conformational change, causing dissociation of the chaperone proteins. The activated drug-receptor complex then translocates to the nucleus.

Within the nucleus, the complex exerts its effects via two principal genomic pathways:

1. Transactivation: The dimerized GR complex binds to specific DNA sequences known as glucocorticoid response elements (GREs) in the promoter regions of target genes. This binding upregulates the transcription of anti-inflammatory proteins. Key proteins induced include:
   • Lipocortin-1 (Annexin-1): Inhibits phospholipase A₂, reducing the release of arachidonic acid, the precursor for prostaglandins and leukotrienes.
   • IκBα: An inhibitor of the transcription factor NF-κB. Increased IκBα sequesters NF-κB in the cytoplasm, preventing its pro-inflammatory gene activation.
   • Interleukin-10 (IL-10): A potent anti-inflammatory cytokine.
2. Transrepression: This mechanism is largely responsible for the therapeutic anti-inflammatory effects. The GR complex directly interacts with and inhibits the activity of pro-inflammatory transcription factors, such as Nuclear Factor-kappa B (NF-κB) and Activator Protein-1 (AP-1), without binding to DNA itself. This interaction represses the transcription of genes encoding cytokines (e.g., IL-1, IL-2, IL-6, TNF-α), chemokines, adhesion molecules, and inflammatory enzymes like cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS).

Non-Genomic Mechanisms

These effects occur within minutes and are likely mediated by membrane-bound GRs or by very high concentrations of the drug interacting with cellular membranes. Non-genomic actions include:

• Rapid inhibition of the release of histamine and other mediators from mast cells and basophils.
• Immediate effects on second messenger systems and ion channels.
• At very high concentrations (often achieved with local injections), a membrane-stabilizing effect may contribute to immediate pain relief.

Cellular and Physiological Effects

The molecular mechanisms translate into broad cellular and systemic effects:

• Anti-inflammatory: Reduction in capillary permeability, edema, and migration of leukocytes (neutrophils, monocytes, lymphocytes) to sites of inflammation.
• Immunosuppressive: Inhibition of T-cell proliferation and function, reduction in antibody production by B-cells, and decreased activity of dendritic cells and macrophages.
• Metabolic: Stimulation of gluconeogenesis, proteolysis, and lipolysis; promotion of glycogen storage; induction of insulin resistance.
• Other: Potentiation of vasoconstrictor response to catecholamines, suppression of the hypothalamic-pituitary-adrenal (HPA) axis, and influence on bone metabolism and electrolyte balance (minimal with triamcinolone).

Pharmacokinetics

The pharmacokinetics of triamcinolone are highly dependent on the route of administration and the specific salt form used. Systemic exposure is generally low with topical, inhaled, and intranasal routes but can be significant with oral administration or from systemic absorption following large or repeated local injections.

Absorption

Absorption varies dramatically by formulation:

• Oral: Triamcinolone base and diacetate are well absorbed from the gastrointestinal tract, with bioavailability estimated to be high, though precise figures are not well established for all salts.
• Parenteral (Intramuscular/Intra-articular/Intralesional): Absorption from injection sites is slow and prolonged due to the low solubility of the acetonide and hexacetonide esters. This creates a depot effect. The rate of absorption determines the duration of action: hexacetonide (slowest) > acetonide > diacetate. Systemic absorption from intra-articular injections is estimated to be approximately 30-50%, which can be sufficient to cause HPA axis suppression with frequent or large joint injections.
• Topical: Percutaneous absorption is influenced by the vehicle, skin integrity, occlusion, and the surface area treated. Absorption is generally low (1-5%) on intact skin but increases significantly on inflamed skin, denuded skin, or under occlusive dressings.
• Inhaled/Intranasal: Systemic absorption occurs primarily from the portion of the dose swallowed and absorbed from the GI tract, as the fraction deposited in the lungs or nasal mucosa undergoes minimal direct absorption into the systemic circulation. Use of a spacer device with inhalers and proper technique minimizes oropharyngeal deposition and systemic bioavailability.

Distribution

Once in the systemic circulation, triamcinolone is widely distributed into body tissues. It crosses the placenta and is distributed into breast milk. Like other corticosteroids, its volume of distribution is moderate. Triamcinolone is approximately 68% bound to plasma proteins, primarily to albumin and corticosteroid-binding globulin (transcortin). This binding is lower than that of cortisol, meaning a higher proportion of free, active drug is available. The drug readily distributes into synovial fluid following systemic administration or local injection.

Metabolism

Triamcinolone undergoes extensive hepatic metabolism, primarily via the cytochrome P450 (CYP) 3A4 isoenzyme. The metabolic pathways include reduction of the 4,5 double bond, reduction of the 3-keto group, and hydroxylation at the 6β position. The 9α-fluoro group is not removed metabolically. The metabolites are predominantly inactive or significantly less active than the parent compound. The metabolism of triamcinolone is not significantly influenced by renal function.

Excretion

The inactive metabolites are excreted mainly in the urine, with a smaller fraction eliminated in the bile and feces. Less than 1% of an administered dose is excreted unchanged in the urine. The elimination is biphasic, with an initial distribution phase followed by a slower terminal elimination phase.

Half-life and Dosing Considerations

The plasma half-life (t_1/2) of triamcinolone is approximately 2-5 hours. However, this metric can be misleading for clinical effect. The biological half-life, which reflects the duration of HPA axis suppression, is considerably longer, typically 18-36 hours. This discrepancy is due to the persistent genomic effects (transrepression/transactivation) long after the drug has been cleared from plasma. For depot injections, the effective half-life is dictated by the slow absorption from the injection site, which can last for weeks. Dosing intervals for oral triamcinolone are typically once daily due to its intermediate biological half-life. Dosing for depot injections varies by indication and site, ranging from every few weeks for intralesional injections to every 3-4 months for intra-articular administration of hexacetonide.

Therapeutic Uses/Clinical Applications

Triamcinolone’s therapeutic applications leverage its potent anti-inflammatory and immunosuppressive effects across multiple organ systems. Its use is guided by the specific formulation and route of administration.

Approved Indications

Dermatology: Topical triamcinolone acetonide is a mainstay for treating inflammatory dermatoses.

• Atopic dermatitis, contact dermatitis, psoriasis, lichen planus, and seborrheic dermatitis.
• Intralesional injection is used for hypertrophic scars, keloids, alopecia areata, granuloma annulare, and cystic acne.

Rheumatology and Orthopedics: Intra-articular and intramuscular injections are frequently employed.

• Intra-articular injection for synovitis and pain in osteoarthritis, rheumatoid arthritis, gouty arthritis, and other inflammatory arthropathies.
• Intrabursal injection for bursitis (e.g., subacromial, trochanteric).
• Intramuscular injection for systemic effect in severe allergic conditions or as a bridge therapy.

Pulmonology and Allergy:

• Inhaled triamcinolone acetonide for the prophylactic management of persistent asthma.
• Intranasal spray for the treatment of seasonal and perennial allergic rhinitis.

Ophthalmology:

• Ophthalmic suspensions and ointments for inflammatory conditions of the eye, including allergic conjunctivitis, uveitis, keratitis, and postoperative inflammation.

Oral Medicine:

• Oral rinse (as triamcinolone acetonide in an adhesive base) for the treatment of aphthous ulcers and other inflammatory oral lesions.

Gastroenterology:

• Off-label, but commonly used for intra-lesional injection of esophageal strictures (e.g., peptic, anastomotic) to reduce recurrence after dilation.

Off-Label Uses

Several off-label applications are supported by clinical evidence and are common in practice:

• Nausea and Vomiting: Used as an adjunctive antiemetic in chemotherapy-induced nausea and vomiting (CINV) protocols and for refractory nausea in palliative care.
• Duchenne Muscular Dystrophy (DMD): Considered a standard of care to slow disease progression and preserve muscle strength and function.
• Prevention of Post-Operative Sore Throat (POST): Intravenous administration may reduce the incidence and severity.
• Lumbar Radiculopathy: Epidural injection (transforminal or interlaminar) for radicular pain, though this remains an area of debate regarding long-term efficacy.
• Chylous Effusions: Intrapleural administration for management of chylothorax.

Adverse Effects

The adverse effect profile of triamcinolone correlates with the dose, duration of therapy, and route of administration. Effects can be localized or systemic.

Common Side Effects

With Local Administration:

• Injection sites: Pain, erythema, subcutaneous atrophy (characterized by a dimpling or depression of the skin), hypopigmentation, sterile abscess, and post-injection flare (acute inflammatory reaction).
• Intra-articular: Transient exacerbation of pain, crystal-induced synovitis (from precipitated steroid ester), and accelerated joint destruction (from overuse masking pain).
• Topical: Skin atrophy, telangiectasias, striae, acneiform eruptions, and perioral dermatitis (especially on the face).
• Inhaled/Intranasal: Oropharyngeal candidiasis, dysphonia, cough, nasal irritation, epistaxis, and nasal septal perforation (rare).
• Ophthalmic: Increased intraocular pressure (steroid-induced glaucoma), posterior subcapsular cataract formation, delayed wound healing, and exacerbation of viral or fungal infections.

With Systemic Absorption (Oral, IM, or from large local doses):

• Fluid and electrolyte disturbances (minimal with triamcinolone due to lack of mineralocorticoid effect).
• Musculoskeletal: Proximal myopathy, osteoporosis, vertebral compression fractures, avascular necrosis of bone (especially femoral head).
• Gastrointestinal: Dyspepsia, peptic ulcer disease (risk increased with concurrent NSAIDs).
• Neuropsychiatric: Insomnia, euphoria, mood swings, depression, psychosis.
• Dermatological: Impaired wound healing, thin fragile skin, easy bruising.
• Metabolic: Hyperglycemia, diabetes mellitus, weight gain with central obesity, hyperlipidemia.
• Immunological: Increased susceptibility to infections, masking of signs of infection.

Serious/Rare Adverse Reactions

• Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression: This is a serious consequence of prolonged systemic therapy or frequent large local injections. It can lead to adrenal insufficiency upon withdrawal of the drug or during physiological stress (surgery, trauma, illness).
• Anaphylactoid Reactions: Rare but reported, particularly with intravenous administration. Some reactions may be related to the ester component or other excipients (e.g., polyethylene glycol).
• Blindness: A catastrophic but rare complication following periocular or intra-articular injections, possibly due to embolism of steroid particles into retinal or cerebral circulation.
• Tendon Rupture: Associated with intratendinous injection or possibly peri-tendinous injection weakening the tendon structure.
• Pancreatitis: Reported with high-dose systemic use.

Black Box Warnings

Triamcinolone injectable suspensions carry a black box warning, which is the strongest safety-related warning mandated by regulatory agencies. The warning highlights:

• Risks of Epidural Injection: Serious neurologic events, including spinal cord infarction, paraplegia, quadriplegia, cortical blindness, stroke, and death, have been reported with epidural injection of corticosteroids. These events have been reported with and without the use of fluoroscopic guidance.
• The safety and effectiveness of epidural administration have not been established, and corticosteroids are not approved for this use. Injection into or near a nerve can cause severe nerve damage.
• Patients should be informed of these potential risks, and the injection should only be performed by experienced clinicians with appropriate training and understanding of the anatomy.

Drug Interactions

Triamcinolone can interact with numerous medications, primarily through pharmacokinetic mechanisms involving CYP450 enzymes and pharmacodynamic synergism or antagonism.

Major Drug-Drug Interactions

Pharmacokinetic Interactions:

• CYP3A4 Inducers: Drugs such as phenobarbital, phenytoin, rifampin, and carbamazepine increase the metabolism of triamcinolone, potentially reducing its therapeutic efficacy. Dose adjustment may be necessary.
• CYP3A4 Inhibitors: Drugs such as ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice can inhibit the metabolism of triamcinolone, leading to increased systemic exposure and a heightened risk of corticosteroid-related adverse effects.
• Anticoagulants: Corticosteroids may alter the response to coumarin anticoagulants (e.g., warfarin), potentially requiring more frequent monitoring of the International Normalized Ratio (INR).

Pharmacodynamic Interactions:

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Concurrent use increases the risk of gastrointestinal ulceration and bleeding. The combination should be used with caution and gastroprotective agents considered.
• Diuretics (especially potassium-depleting, e.g., thiazides, loop diuretics): Corticosteroids can enhance potassium excretion. Triamcinolone has minimal mineralocorticoid effect, but the risk of hypokalemia may still be increased.
• Antidiabetic Agents (Insulin, Oral Hypoglycemics): Triamcinolone antagonizes the action of insulin and can cause hyperglycemia, necessitating dose adjustments of antidiabetic medications.
• Vaccines (Live-Attenuated): Immunosuppressive doses of triamcinolone can impair the immune response to live vaccines (e.g., MMR, varicella, yellow fever) and increase the risk of vaccine-associated infection. Administration of live vaccines is generally contraindicated.
• Neuromuscular Blocking Agents: Corticosteroids may potentiate or antagonize the effects of these agents, though reports are variable.

Contraindications

Absolute contraindications to triamcinolone therapy are relatively few but critical:

• Systemic Fungal Infections: Unless used for the management of drug reactions (e.g., amphotericin B infusion reactions).
• Known Hypersensitivity: To triamcinolone, any of its ester forms, or any component of the formulation.
• Intrathecal or Intradermal Administration: Of the injectable suspension is contraindicated due to severe local tissue damage and neurological complications.
• Live Virus Vaccination: During immunosuppressive corticosteroid therapy.
• Ophthalmic Use in Viral, Fungal, or Mycobacterial Infections of the Eye: Such as dendritic keratitis (herpes simplex).

Relative contraindications require careful risk-benefit assessment and include: active or latent tuberculosis, active peptic ulcer disease, uncontrolled hypertension, congestive heart failure, diabetes mellitus, osteoporosis, psychosis, and glaucoma.

Special Considerations

The use of triamcinolone requires careful evaluation in specific patient populations due to altered pharmacokinetics, increased susceptibility to adverse effects, or potential teratogenic risks.

Pregnancy and Lactation

Pregnancy (FDA Category C): Animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans. Glucocorticoids, including triamcinolone, may cross the placenta. Chronic use during pregnancy has been associated with an increased risk of intrauterine growth restriction (IUGR) and low birth weight. A potential risk of cleft palate exists with first-trimester exposure, though the absolute risk is considered low. Triamcinolone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. When systemic therapy is required, agents with lower placental transfer (e.g., prednisone, prednisolone) are often preferred. Local administration (topical, inhaled, intra-articular) minimizes systemic exposure and is generally considered to have a lower risk profile.

Lactation: Triamcinolone is excreted in human milk in small amounts. Systemic corticosteroids administered in pharmacologic doses could cause growth suppression, interfere with endogenous corticosteroid production, or have other undesirable effects in a nursing infant. The decision to discontinue nursing or the drug should consider the importance of the drug to the mother. Topical application to the breasts should be avoided prior to nursing to prevent direct infant ingestion.

Pediatric Considerations

Children are particularly susceptible to the adverse effects of corticosteroids, especially growth suppression. Chronic use, even with inhaled formulations, can impair linear growth. Growth should be monitored regularly in pediatric patients on prolonged therapy. The use of alternate-day dosing when possible may reduce this risk. Behavioral changes, including psychosis, may occur more frequently in children. Dosing must be carefully calculated based on body surface area or weight, not age. The benefits of intra-articular injections for juvenile idiopathic arthritis must be weighed against the risk of systemic absorption and local effects on the growth plate if injected inadvertently.

Geriatric Considerations

Elderly patients may be more susceptible to certain adverse effects, particularly osteoporosis, hypertension, hyperglycemia, and fluid retention. Age-related decreases in hepatic and renal function may alter the pharmacokinetics, though this is not typically clinically significant for triamcinolone. The increased prevalence of comorbidities and polypharmacy in this population elevates the risk of drug interactions. The lowest effective dose for the shortest duration should be employed. Bone density monitoring and prophylactic measures against osteoporosis (e.g., calcium, vitamin D, bisphosphonates) should be considered for those on chronic systemic therapy.

Renal and Hepatic Impairment

Renal Impairment: Dose adjustment is not typically required for triamcinolone in renal impairment, as the drug and its inactive metabolites are cleared hepatically. However, caution is warranted because corticosteroids can cause sodium and water retention, which may exacerbate hypertension or heart failure. The risk of hypokalemia, though minimal with triamcinolone, may be additive with other conditions or drugs affecting potassium balance.

Hepatic Impairment: Since triamcinolone is extensively metabolized in the liver, significant hepatic impairment could theoretically reduce its clearance and increase systemic exposure. However, specific dosing guidelines are not well established. In patients with cirrhosis, hypoalbuminemia may increase the fraction of free, active drug. Clinical monitoring for signs of corticosteroid excess is prudent, and dose reduction may be necessary.

Summary/Key Points

Triamcinolone is a versatile, intermediate-potency synthetic glucocorticoid with a distinct pharmacologic profile characterized by potent anti-inflammatory action and negligible mineralocorticoid activity.

• It is classified as a fluorinated glucocorticoid, available as several esterified salt forms (acetonide, hexacetonide, diacetate) that dictate solubility, duration of action, and appropriate route of administration.
• The primary mechanism of action involves binding to the intracellular glucocorticoid receptor, leading to genomic effects (transactivation and transrepression) that suppress the synthesis of key inflammatory mediators. Non-genomic effects contribute to rapid responses.
• Pharmacokinetics are route-dependent. Systemic absorption from local sites (injections, topical) can be significant. It is metabolized hepatically by CYP3A4 and excreted renally as inactive metabolites. The biological half-life (18-36 hours) exceeds the plasma half-life.
• Major therapeutic applications span dermatology (topical, intralesional), rheumatology (intra-articular), pulmonology/allergy (inhaled, intranasal), and ophthalmology. Off-label uses include antiemesis and Duchenne muscular dystrophy.
• Adverse effects range from local tissue atrophy and hypopigmentation to systemic effects like HPA axis suppression, hyperglycemia, osteoporosis, and increased infection risk. Injectable forms carry a black box warning for serious neurologic events with epidural administration.
• Significant drug interactions occur with CYP3A4 inducers/inhibitors, NSAIDs, anticoagulants, and antidiabetic agents. Use is contraindicated in systemic fungal infections and for intrathecal injection.
• Special caution is required in pediatric patients (growth suppression), the elderly (increased susceptibility to metabolic and bone effects), and during pregnancy/lactation. Dose adjustment is not routinely required for renal or hepatic impairment, but clinical vigilance is necessary.

Clinical Pearls

• When injecting triamcinolone acetonide or hexacetonide subcutaneously, use a high concentration/low volume to minimize the risk of subcutaneous atrophy.
• For intra-articular injections, strict aseptic technique is paramount to prevent septic arthritis. The number of injections into a single joint should generally be limited to 3-4 per year to reduce the risk of osteonecrosis and cartilage damage.
• Patients on chronic inhaled triamcinolone for asthma should be instructed to rinse their mouth and gargle with water after each use to reduce the risk of oropharyngeal candidiasis and dysphonia.
• Systemic absorption from topical steroids is a real concern, especially when used on large body surface areas, under occlusion, or on broken skin. The “fingertip unit” can help guide appropriate dosing to minimize this risk.
• Always consider and discuss the black box warning regarding neurologic risks prior to any epidural or perineural injection of triamcinolone suspension.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.